Business
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida. To schedule a 1x1 meeting with the Company, please contact your Leeri
About this update from Eton Pharmaceuticals, Inc.
[{"type":"image","alt":"Eton Pharmaceuticals","displaySize":"","headline":null,"caption":"Eton Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":159,"url":"https://media.zenfs.com/en/globenewswire.com/a0621e3acb49a158aa77f271568b8ffd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a2q.GJ3zLE98lva_7jreig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a0621e3acb49a158aa77f271568b8ffd","width":300,"height":159}},"lazy":false},{"type":"text","content":"DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida.","length":430,"tagName":"p"},{"type":"text","content":"To schedule a 1x1 meeting with the Company, please contact your Leerink Partners institutional sales representative.","length":116,"tagName":"p"},{"type":"text","content":"About Eton PharmaceuticalsEton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.","length":542,"tagName":"p"},{"type":"text","content":"Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: [email protected]","length":106,"tagName":"p"},{"type":"text","content":"Source: Eton Pharmaceuticals.","length":29,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]